Blog
RSS FeedPosted by Michael Wonder on 07 Nov 2022
Can we use existing guidance to support the development of robust real world evidence for health technology assessment/payer decision-making?
2 November 2022 - Advances in the digitisation of health systems and expedited regulatory approvals of innovative treatments have led to ...
Posted by Michael Wonder on 14 Sep 2022
Has there actually been early resolution for early resolution resubmissions?
15 September 2022 - Following on from this week's article on early re-entry resubmissions, today we took a close look ...
Posted by Michael Wonder on 08 Sep 2022
Large scale population based surveys linked to administrative health databases as a source of data on health utilities in Australia
8 September 2022 - It is ideal that modelling studies apply health utility values that are compatible, derived using common methods, ...
Posted by Michael Wonder on 08 Sep 2022
Is IQWiG's 15% threshold universally applicable in assessing the clinical relevance of patient reported outcomes changes? An ISPOR Special Interest Group report.
8 September 2022 - To assess the clinical relevance of patient reported outcomes, a response threshold of ≥ 15% of the ...
Posted by Michael Wonder on 08 Sep 2022
Esketamine: NICE’s appraisal was unfair, appeal panel rules
8 September 2022 - The decision by the UK National Institute for Health and Care Excellence not to recommend esketamine ...
Posted by Michael Wonder on 07 Sep 2022
Doctors call for vaccine u-turn from PHARMAC after surge in preventable pneumococcal cases
8 September 2022 - When drug-buying agency PHARMAC switched to a cheaper vaccine covering fewer strains of potentially deadly pneumococcal ...
Posted by Michael Wonder on 06 Sep 2022
ICR criticises NICE rejection of olaparib for advanced prostate cancer
6 September 2022 - The Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not ...
Posted by Michael Wonder on 05 Sep 2022
PHARMAC releases its interim response following PHARMAC review
5 September 2022 - As part of its ongoing commitment to transparency, Te Pātaka Whaioranga – PHARMAC has today shared their ...
Posted by Michael Wonder on 17 Aug 2022
UK will not buy Evusheld owing to “insufficient data” on protection, Government says
15 August 2022 - The UK Government has said that it will not procure the COVID-19 drug Evusheld—a combination of ...
Posted by Michael Wonder on 11 Jul 2022
The (harsh) reality of real-world data external comparators for health technology assessment
8 July 2022 - We read with great interest the recently published article by Patel et al. and commend the authors ...
Posted by Michael Wonder on 15 Jun 2022
PHARMAC announces first round of medicine funding decisions following $191 million pharmaceutical budget increase
15 June 2022 - PHARMAC today announces the first round of changes to medicines funding following its $191 million pharmaceutical ...
Posted by Michael Wonder on 09 Jun 2022
The days of the independent republic of PHARMAC are far from over
9 June 2022 - When he announced the government’s response to the recent independent review of PHARMAC Health Minister Andrew Little ...
Posted by Michael Wonder on 25 May 2022
Target trial emulation for transparent and robust estimation of treatment effects for health technology assessment using real world data: opportunities and challenges
25 May 2022 - Evidence about the relative effects of new treatments is typically collected in randomised controlled trials. ...
Posted by Michael Wonder on 19 May 2022
Multiple funding proposals being considered by PHARMAC
19 May 2022 - PHARMAC has issued three consultations today on proposals to fund medicines for conditions including cancer, multiple sclerosis, ...
Posted by Michael Wonder on 09 May 2022
Choices that fail health and wellbeing
5 May 2022 - NICE's expert group RAPID C-19, set up to ‘to ensure safe and timely patient access to treatments ...